TrialFrontiers in immunology2021

Efficacy and Safety of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Antibody-Mediated Rejection After Kidney Transplantation- A Single-Arm, Two-Dosing-Regimen, Phase I/II Study.

Yongcheng Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.